A Randomized, Open-Label, Two-Period, Parallel Group, Crossover Study to Evaluate the Pharmacokinetics of Venlafaxine Extended-Release and DVS SR in Healthy Subjects Who Are Extensive or Poor Cytochrome P450 2D6 Substrate Metabolizers.

Trial Profile

A Randomized, Open-Label, Two-Period, Parallel Group, Crossover Study to Evaluate the Pharmacokinetics of Venlafaxine Extended-Release and DVS SR in Healthy Subjects Who Are Extensive or Poor Cytochrome P450 2D6 Substrate Metabolizers.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jan 2011

At a glance

  • Drugs Desvenlafaxine; Venlafaxine
  • Indications Depression; Depressive disorders; Fibromyalgia; Generalised anxiety disorder; Major depressive disorder; Menopause; Neuropathic pain; Panic disorder; Social phobia; Vasomotor symptoms
  • Focus Pharmacogenomic; Pharmacokinetics
  • Sponsors Wyeth
  • Most Recent Events

    • 10 Jun 2010 Results presented at the 27th International Congress of Collegium Internationale Neuro Psychopharmacologicum.
    • 12 Sep 2009 Results presented at the 22nd Annual Congress of the European College of Neuropsychopharmacology (ECNP 2009).
    • 28 Jun 2009 Results presented at the 9th World Congress of Biological Psychiatry 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top